- Home
- OCFT vs ANL Comparison
OCFT vs ANL Comparison
Compare OCFT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- ANL
- Stock Information
- Founded
- OCFT 2015
- ANL 2004
- Country
- OCFT China
- ANL Cayman Islands
- Employees
- OCFT N/A
- ANL N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- ANL
- Sector
- OCFT Technology
- ANL
- Exchange
- OCFT Nasdaq
- ANL Nasdaq
- Market Cap
- OCFT 102.5M
- ANL 79.0M
- IPO Year
- OCFT 2019
- ANL 2023
- Fundamental
- Price
- OCFT $2.69
- ANL $2.34
- Analyst Decision
- OCFT Strong Buy
- ANL Strong Buy
- Analyst Count
- OCFT 1
- ANL 2
- Target Price
- OCFT $7.00
- ANL $9.00
- AVG Volume (30 Days)
- OCFT 29.3K
- ANL 7.6K
- Earning Date
- OCFT 11-14-2024
- ANL 08-08-2024
- Dividend Yield
- OCFT N/A
- ANL N/A
- EPS Growth
- OCFT N/A
- ANL N/A
- EPS
- OCFT 0.00
- ANL N/A
- Revenue
- OCFT $407,825,504.00
- ANL $5,000,000.00
- Revenue This Year
- OCFT N/A
- ANL N/A
- Revenue Next Year
- OCFT N/A
- ANL N/A
- P/E Ratio
- OCFT $27.02
- ANL N/A
- Revenue Growth
- OCFT N/A
- ANL N/A
- 52 Week Low
- OCFT $0.87
- ANL $1.85
- 52 Week High
- OCFT $4.98
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- OCFT 55.45
- ANL 47.04
- Support Level
- OCFT $2.29
- ANL $2.11
- Resistance Level
- OCFT $2.87
- ANL $2.30
- Average True Range (ATR)
- OCFT 0.24
- ANL 0.14
- MACD
- OCFT 0.02
- ANL 0.01
- Stochastic Oscillator
- OCFT 65.82
- ANL 52.47
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a provider of technology platforms. Its platform provides cloud-native technology solutions that integrate financial services with market technology. The company offers technology applications and technology-enabled business services to financial institutions in China. Its technology solutions cover multiple verticals in the financial services industry, including banking, insurance and asset management, across the full scope of their businesses from sales and marketing and risk management to customer services and operations, as well as technology infrastructures such as data management and cloud services. The firm operates in two segments namely Technology Solutions which is the key revenue driver and Virtual Bank Business.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.